Alembic Pharma targets 10-15% US growth in FY27

US business becomes the core growth lever

Alembic Pharmaceuticals is positioning its US generics franchise as the main driver for its next phase of growth, supported by a steady launch pipeline and what management describes as improving execution. Managing Director Pranav Amin told Moneycontrol the company sees the US business “well set for 10-15 percent growth” on the back of new launches and market share gains. This outlook sits alongside broader management commentary pointing to low double-digit consolidated revenue growth in the current fiscal. The company is also leaning on a revival in exports and stabilisation across key segments to support overall performance. After a subdued phase, the US trajectory has become central because it is now the single-largest segment by revenue. Investors and analysts are watching this segment closely given persistent price pressures in the US generics market.

FY26 showed traction, but growth rates vary by source

The company’s US business showed signs of traction in FY26, with management indicating 13% growth driven by both pricing and volumes. Separately, Motilal Oswal noted that US sales growth in FY26 was 7% year-on-year in constant currency terms despite a healthy pace of launches. While the growth rates differ across disclosures and measures, the underlying message is consistent: the US business is improving and is expected to remain the key growth driver. Investor presentation data shows the US business contributed Rs 2,206 crore to FY26 revenue, translating into a 30% share and making it the largest segment. That scale matters because incremental volume and better capacity utilisation can feed into operating leverage. Alembic’s leadership is also highlighting share gains in select products and more reliable launch execution.

Launch pipeline: 15+ launches this fiscal, 30 planned

Amin said Alembic is planning 15-plus launches in the US this fiscal, including limited-competition opportunities. He also indicated that near-term growth could be supported by day-one launch opportunities in select molecules. Equirus highlighted upcoming high-value launches such as generic Bosulif, generic Adempas and generic Selexipag, and also pointed to 30 planned launches. If executed on time, a larger launch cadence can improve plant utilisation and support margin recovery, especially when products face fewer competitors. Management commentary also suggests international product launches will be phased through FY27, with a few meaningful day-one launches expected in the first couple of quarters. For investors, the quality and competitiveness of launches typically matters as much as the headline number of products.

Margin roadmap: targeting ~20% EBITDA in 2-3 years

Alembic expects margins to improve gradually and has reiterated an aspiration to reach about 20% EBITDA margins over the next two to three years. The stated drivers include scale benefits, better capacity utilisation and the contribution of high-value launches. Motilal Oswal also noted management expects margin improvement in FY27, while flagging lower operating leverage in its own estimates. The broader industry context remains challenging, with India’s generic drugmakers facing margin pressure due to lower prices in the US amid intense competition. Against that backdrop, Alembic’s margin targets imply the company is counting on a mix shift, smoother execution and improved utilisation rather than a sharp pricing recovery. Management has also indicated a preference for sweating existing assets rather than pursuing aggressive fresh capex.

Beyond the US: RoW and API support, India lags

Outside the US, Alembic is leaning on a diversified portfolio. The rest-of-world (RoW) business grew 20% in FY26 and is expected by management to sustain about 15% growth, while the API segment is expected to grow around 10% with steady, modest expansion. India remains the weak spot in the near term. Domestic revenue grew just 4-5%, with pressure in key therapy segments, and management said the immediate focus is to return to market-level growth before aiming to outperform. Earlier disclosures also showed India’s formulation business grew 6.1% in FY25 to Rs 2,339 crore, below the Indian pharmaceutical market growth of 8.4% in FY25, with the company attributing slower growth to a volume drop in the acute segment. The near-term execution challenge is therefore twofold: protect US momentum while repairing domestic growth.

Financial snapshot: FY26 scale and FY27 investment plans

Motilal Oswal said that for FY26, revenue, EBITDA and PAT rose 10%, 11% and 9% year-on-year to INR73b, INR11b and INR6b, respectively. Normalised, that equates to Rs 7,300 crore revenue, Rs 1,100 crore EBITDA and Rs 600 crore PAT. Management also indicated FY27 R&D investments of around INR7.5-8.0b, or Rs 750-800 crore, representing about 9% of revenue in that commentary. FY27 capex is expected at INR3.0-3.5b, or Rs 300-350 crore, primarily for capacity expansion, debottlenecking and replacement capex. The emphasis on debottlenecking and utilisation aligns with the margin recovery plan laid out by management. It also suggests Alembic expects meaningful output improvements without a dramatic step-up in spending.

Street view: Equirus sees mid-teen growth, Motilal stays Neutral

Equirus expects the US to remain a key growth driver and has modelled mid-teen growth over the next two years supported by a strong pipeline of launches. Motilal Oswal maintained a Neutral view with a target price of INR725, valuing the stock at 14x 12-month forward earnings. Motilal said it cut earnings estimates by 12% and 6% for FY27 and FY28, respectively, factoring in lower operating leverage. It also noted Alembic ended FY26 with earnings growth of 9% year-on-year and estimated a CAGR of 21% and 26% in EBITDA and PAT over FY26-28, considering a scale-up in the US business and momentum in non-US and API segments. However, Motilal added that current valuation adequately captures potential upside in earnings, underpinning its Neutral stance. The mix of growth optimism and valuation caution reflects how closely execution will be tracked in FY27.

Stock triggers: USFDA approval lifts sentiment

Alembic Pharma shares rose 2.3% on Tuesday after the company received US Food & Drug Administration final approval for its Abbreviated New Drug Application (ANDA) for Macitentan Tablets. Regulatory approvals remain important near-term triggers for Indian pharma stocks because they can translate into launches, new revenue streams and better asset utilisation. The company has previously stated it has establishment inspection reports for all facilities and no regulatory overhang, which can reduce uncertainty around launch timelines. Even so, approvals are only one part of the equation, as pricing, competition intensity and channel execution typically decide the eventual profitability of a product.

Key numbers at a glance

What to watch through FY27

Alembic’s FY27 narrative is tightly linked to execution in the US: timely launches, better day-one participation where available, and a mix that supports margins. RoW and API appear positioned as stabilisers, with management guiding for double-digit growth in both, while India is a repair job aimed first at matching market growth. The company’s margin aspiration of ~20% EBITDA over two to three years sets a measurable benchmark, especially given ongoing US price erosion in the sector. Investor focus is likely to remain on the cadence and quality of launches, market share gains in existing products, and whether capacity utilisation improves enough to lift profitability. The next set of updates on launch rollouts and segment growth trends will be key to validating the guidance and analyst models.